# Ipamorelin: The Newest Research on a Selective GH Peptide > Ipamorelin is the first selective growth hormone secretagogue. A research digest leading with the 2024-2026 literature and the foundational pharmacology — every claim cited. A literature-led reading of the 2024-2026 work alongside the 1998 founding pharmacology: what each study measured, in which species, with every quantitative claim cited. ## Start here Ipamorelin is a small lab-made peptide — a chain of five amino acids — that tells the pituitary gland to release a pulse of growth hormone. What makes it stand out is how *cleanly* it does this: in animal studies it raised growth hormone without meaningfully raising the stress hormone cortisol or the milk hormone prolactin, which older peptides in its family could not avoid. That is why researchers call it "selective." The newest reviews and studies, from 2024 through 2026, are the freshest part of the picture and where this site leads. They keep landing on the same two notes: the biology is real and interesting, but the human evidence is thin. Ipamorelin was tested in people once, for slow bowel recovery after surgery, and that trial did not work. It has never been approved as a medicine anywhere. People still use it off-label, often paired with a partner peptide, and what they report — the upsides and the downsides — is laid out on [the effects page](/effects). Everything below is a summary of published studies, not medical advice. ## What the newest ipamorelin research actually says The most recent published in-vivo study of Ipamorelin, from 2024, gave the peptide to ferrets to test it against the weight loss that chemotherapy causes. Intraperitoneal ipamorelin at 1-3 mg/kg cut cisplatin-induced body-weight loss by about 24% on the last day of the delayed phase (48-72 hours), though it produced no anti-emetic effect — it did not reduce vomiting at all [5]. That single result captures the shape of the whole field: a measurable metabolic signal through the ghrelin receptor (the same receptor the hunger hormone ghrelin uses), paired with a clear limit on what the molecule does. The 2026 review wave reinforces that reading. A narrative review aimed at orthopaedic and sports-medicine physicians reported that CJC-1295 combined with ipamorelin significantly improved maximal muscle tetanic tension in a glucocorticoid-induced muscle-loss model in mice [12]. Two further 2026 reviews — one in orthopaedics, one in gerontology — group ipamorelin with non-approved peptides that lack long-term human safety data, and call explicitly for rigorous clinical evaluation before any adoption [13][14]. The frontier is animal data and review synthesis, not human outcome trials. ## The founding pharmacology — still the anchor Ipamorelin's defining paper is from 1998. In primary rat pituitary cells, anaesthetised rats, and conscious swine, it released growth hormone potently — a swine ED50 of 2.3 nmol/kg, against 3.9 nmol/kg for the older peptide GHRP-6 — yet did not raise ACTH (the hormone that drives cortisol) or cortisol above the level seen with GHRH, even at doses more than 200-fold above its growth-hormone ED50 [1]. That selectivity is the reason the peptide exists. The human pharmacokinetic picture is narrow but precise. In healthy male volunteers given single 15-minute intravenous infusions (4.21-140.45 nmol/kg), kinetics were dose-proportional, the terminal half-life was about 2 hours, and the growth-hormone response arrived as one discrete pulse peaking near 40 minutes after dosing [2]. The full mechanism is on the [Ipamorelin research](/research) page; the dose ranges studied — always in third-person, study-attributed terms — are on the [dosage page](/dosage). ## Why this site exists — and what it is not This domain carries the word "telehealth," but it provides no telehealth, no consultations, and no prescriptions. It is an editorial digest: a plain-English reading of the published Ipamorelin literature, organized so a curious non-scientist and a researcher can both find what the studies measured. We do not sell anything and we do not employ clinicians. The pages that follow break the record apart. The [benefits page](/benefits) collects the effects reported in research — clearly separating what studies measured from what users describe. The [how-it-works page](/how-it-works) walks the mechanism in plain words. And what people report — including the downsides — is on [the effects page](/effects), where it is labeled as anecdote and kept separate from the cited findings. --- A recent-research reading of the ipamorelin literature — the freshest 2024-2026 studies up front, the lone failed human trial and the missing long-term safety kept in plain sight, and the community reports pinned off to one side as anecdote; no telehealth, no clinic, no prescription, and nothing here dosed or dispensed.